Selatogrel

Selatogrel
Clinical data
Other names	ACT-246475
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name [(2R)-3-(4-butoxycarbonylpiperazin-1-yl)-2-[[6-[(3S)-3-methoxypyrrolidin-1-yl]-2-phenylpyrimidine-4-carbonyl]amino]-3-oxopropyl]phosphonic acid;
CAS Number	1159500-34-1 ;
PubChem CID	59534142 ;
UNII	6DPK7O4PR7 ;
ChEMBL	ChEMBL4297589 ;
Chemical and physical data
Formula	C28H39N6O8P
Molar mass	618.628 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES CCCCOC(=O)N1CCN(CC1)C(=O)[C@H](CP(=O)(O)O)NC(=O)C2=CC(=NC(=N2)C3=CC=CC=C3)N4CC[C@@H](C4)OC;
	InChI InChI=1S/C28H39N6O8P/c1-3-4-16-42-28(37)33-14-12-32(13-15-33)27(36)23(19-43(38,39)40)30-26(35)22-17-24(34-11-10-21(18-34)41-2)31-25(29-22)20-8-6-5-7-9-20/h5-9,17,21,23H,3-4,10-16,18-19H2,1-2H3,(H,30,35)(H2,38,39,40)/t21-,23-/m0/s1; Key:FYXHWMQPCJOJCH-GMAHTHKFSA-N;

Last updated June 30, 2025

Selatogrel is a P2Y₁₂ inhibitor^[1]^[2] that has been proposed as a treatment for acute myocardial infarction.^[3]

References

↑ Milluzzo RP, Franchina GA, Capodanno D, Angiolillo DJ (June 2020). "Selatogrel, a novel P2Y₁₂ inhibitor: a review of the pharmacology and clinical development". Expert Opinion on Investigational Drugs. 29 (6): 537–546. doi:10.1080/13543784.2020.1764533. PMID 32396484.
↑ Parker WA, Storey RF (March 2020). "Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y₁₂ receptor antagonist". Expert Opinion on Emerging Drugs. 25 (1): 1–6. doi:10.1080/14728214.2020.1729121. PMID 32064955.
↑ Gehin M, Storey RF, Bernaud C, Dingemanse J (2023). "Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction". Expert Opinion on Drug Metabolism & Toxicology. 19 (10): 697–708. doi: 10.1080/17425255.2023.2266384 . PMID 37795868.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Milluzzo RP, Franchina GA, Capodanno D, Angiolillo DJ (June 2020). "Selatogrel, a novel P2Y₁₂ inhibitor: a review of the pharmacology and clinical development". Expert Opinion on Investigational Drugs. 29 (6): 537–546. doi:10.1080/13543784.2020.1764533. PMID 32396484.

[2] Parker WA, Storey RF (March 2020). "Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y₁₂ receptor antagonist". Expert Opinion on Emerging Drugs. 25 (1): 1–6. doi:10.1080/14728214.2020.1729121. PMID 32064955.

[3] Gehin M, Storey RF, Bernaud C, Dingemanse J (2023). "Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction". Expert Opinion on Drug Metabolism & Toxicology. 19 (10): 697–708. doi: 10.1080/17425255.2023.2266384 . PMID 37795868.

[1]

[2]

[3]